SCHEMBL10134770

SCHEMBL10134770

N#Cc1ccc2c(c1)nc(Nc1cccc(F)c1)c1cscc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 7/20 0.45
CSNK2A2 P19784 4/20 0.45
CSNK2B P67870 4/20 0.45
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
ABCG2 Q9UNQ0 6/20 0.44
SYK P43405 1/20 0.43
CSNK2A3 Q8NEV1 1/20 0.42
JAK2 O60674 1/20 0.42
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134755 0.87 CSNK2A1 (0.45) CSNK2A1CSNK2A2CSNK2BKDM4EABCG2
SCHEMBL10134753 0.87 ABCG2 (0.43) CSNK2A1CSNK2A2CSNK2BALDH1A1KDM4E
SCHEMBL10134767 0.87 TDO2 (0.49) CSNK2A1CSNK2A2CSNK2BABCG2TP53
SCHEMBL10134763 0.83 CSNK2A1 (0.46) CSNK2A1CSNK2A2CSNK2BABCG2EGFR
SCHEMBL13688025 0.83 EGFR (0.60) CSNK2A1CSNK2A2CSNK2BALDH1A1KDM4E
SCHEMBL2689904 0.82 CSNK2A1 (0.67) CSNK2A1CSNK2B
SCHEMBL10134757 0.81 CSNK2A1 (0.42) CSNK2A1CSNK2A2CSNK2BALDH1A1KDM4E
SCHEMBL10135169 0.75 CSNK2A1 (0.59) CSNK2A1CSNK2A2CSNK2BALDH1A1KDM4E
SCHEMBL10134783 0.74 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BALDH1A1KDM4E
SCHEMBL30486954 0.74 ABCG2 (0.51) CSNK2A1CSNK2A2CSNK2BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 CSNK2A1 680/4885CSNK2A2 810/4885CSNK2B 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.